Bayer Acquires Perfuse Therapeutics for $2.45B

Bayer is significantly bolstering its ophthalmology portfolio through a strategic acquisition of Perfuse Therapeutics, a deal valued at up to $2.45 billion. This move signals a strong commitment from the pharmaceutical giant to address critical unmet needs in vision care, particularly for conditions linked to ischemia.

The transaction structure includes an initial payment of $300 million, with the remainder contingent upon the successful achievement of development, regulatory, and commercial milestones. This performance-based component underscores the potential perceived in Perfuse Therapeutics' lead asset, PER-001.

PER-001, an investigational small molecule targeting endothelin receptors, is currently advancing through Phase II clinical trials for glaucoma and diabetic retinopathy. Unlike conventional treatments that primarily focus on reducing intraocular pressure, PER-001 aims to modify the disease process itself by combating ischemia and mitigating visual impairment. This novel approach could represent a paradigm shift in treating these prevalent blinding conditions.

The global burden of these diseases is substantial. Glaucoma affects an estimated 76 million to 80 million individuals worldwide, standing as the foremost cause of irreversible vision loss. Diabetic retinopathy impacts approximately 146 million people globally, with a significant subset of 25 million experiencing vision-threatening complications. The development of disease-modifying therapies like PER-001 holds immense promise for improving patient outcomes and reducing the societal cost of blindness.

PER-001 is engineered as a sustained-release intravitreal implant, designed for convenient administration via a single-use applicator. Its mechanism of action targets endothelin receptors, which play a role in vasoconstriction, inflammation, and cellular damage implicated in various ocular pathologies. This targeted therapy aligns with Bayer's strategic imperative to expand its presence in high-impact therapeutic areas with significant patient needs.

This acquisition not only enhances Bayer's pipeline but also integrates the expertise of the Perfuse Therapeutics team. Dr. Juergen Eckhardt, Head of Business Development and Licensing at Bayer Pharmaceuticals, expressed enthusiasm for the potential of PER-001 and the synergy with Bayer's existing ophthalmology capabilities. Dr. Sevgi Gurkan, Founder and CEO of Perfuse Therapeutics, highlighted Bayer's global reach as crucial for realizing the full potential of their innovative therapy.

The transaction is subject to customary closing conditions, including regulatory approvals and shareholder consent. BofA Securities advised Bayer on the transaction, while Centerview Partners provided advisory services to Perfuse Therapeutics.